Organ Preservation in Rectal Cancer.
Nonoperative management
Organ preservation
Rectal cancer
Watch-and-wait
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
03
2020
accepted:
22
03
2020
pubmed:
22
4
2020
medline:
15
4
2021
entrez:
22
4
2020
Statut:
ppublish
Résumé
A proportion of patients with rectal cancer who undergo neoadjuvant treatment end up with a complete pathological response. Because these patients have excellent oncological outcomes, many have questioned if surgical treatment in this population constitutes overtreatment. There is growing interest in watch and wait with selective organ preservation for rectal cancer patients. We review the fundamentals and key considerations of this approach including patient selection, available treatment regimens, assessment of response, long-term monitoring of response, and long-term oncological and functional outcomes.
Identifiants
pubmed: 32314234
doi: 10.1007/s11605-020-04583-w
pii: 10.1007/s11605-020-04583-w
pmc: PMC7390702
mid: NIHMS1586105
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1880-1888Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009501
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Références
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40. https://doi.org/10.1056/NEJMoa040694 .
doi: 10.1056/NEJMoa040694
pubmed: 15496622
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. Lancet. 2010;375(9719):1030–47. https://doi.org/10.1016/S0140-6736(10)60353-4 .
doi: 10.1016/S0140-6736(10)60353-4
pubmed: 20304247
Pucciarelli S, Del Bianco P, Efficace F, Serpentini S, Capirci C, De Paoli A et al. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg. 2011;253(1):71–7. https://doi.org/10.1097/SLA.0b013e3181fcb856 .
doi: 10.1097/SLA.0b013e3181fcb856
pubmed: 21135694
Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015;14(2):106–14. https://doi.org/10.1016/j.clcc.2014.12.007 .
doi: 10.1016/j.clcc.2014.12.007
pubmed: 25677122
Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767. https://doi.org/10.1186/s12885-015-1632-z .
doi: 10.1186/s12885-015-1632-z
pubmed: 26497495
pmcid: 4619249
Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44. https://doi.org/10.1016/S1470-2045(10)70172-8 .
doi: 10.1016/S1470-2045(10)70172-8
pubmed: 20692872
Garcia-Aguilar J, Shi Q, Thomas CR, Jr., Chan E, Cataldo P, Marcet J et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012;19(2):384–91. https://doi.org/10.1245/s10434-011-1933-7 .
doi: 10.1245/s10434-011-1933-7
pubmed: 21755378
Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66. https://doi.org/10.1016/S1470-2045(15)00004-2 .
doi: 10.1016/S1470-2045(15)00004-2
pubmed: 26187751
pmcid: 4670237
Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30(15):1770–6. https://doi.org/10.1200/JCO.2011.39.7901 .
doi: 10.1200/JCO.2011.39.7901
pubmed: 22493423
pmcid: 3383178
Janeway H. Treatment of cancer, particularly of the tongue, tonsil and rectum, by buried emanation. Am J Roentgenol. 1920;7:92.
Binkley GE. Radiation in the treatment of rectal cancer. Ann Surg. 1929;90(6):1000–14. https://doi.org/10.1097/00000658-192912000-00007 .
doi: 10.1097/00000658-192912000-00007
pubmed: 17866218
pmcid: 1398957
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silvae Sousa AH, Jr. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7; discussion 7-8. https://doi.org/10.1097/01.sla.0000141194.27992.32 .
doi: 10.1097/01.sla.0000141194.27992.32
pubmed: 15383798
pmcid: 1356472
Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40. https://doi.org/10.1200/JCO.2011.37.7176 .
doi: 10.1200/JCO.2011.37.7176
pubmed: 22067400
Araujo RO, Valadao M, Borges D, Linhares E, de Jesus JP, Ferreira CG et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015;41(11):1456–63. https://doi.org/10.1016/j.ejso.2015.08.156 .
doi: 10.1016/j.ejso.2015.08.156
pubmed: 26362228
Martens MH, Maas M, Heijnen LA, Lambregts DM, Leijtens JW, Stassen LP et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108(12). https://doi.org/10.1093/jnci/djw171 .
Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, Jorgensen JC et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–27. https://doi.org/10.1016/S1470-2045(15)00120-5 .
doi: 10.1016/S1470-2045(15)00120-5
pubmed: 26156652
Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256(6):965–72. https://doi.org/10.1097/SLA.0b013e3182759f1c .
doi: 10.1097/SLA.0b013e3182759f1c
pubmed: 23154394
Ayloor Seshadri R, Kondaveeti SS, Jayanand SB, John A, Rajendranath R, Arumugam V et al. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology. 2013;60(123):410–4. https://doi.org/10.5754/hge12354 .
doi: 10.5754/hge12354
pubmed: 23635444
Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83. https://doi.org/10.1016/S1470-2045(15)00467-2 .
doi: 10.1016/S1470-2045(15)00467-2
pubmed: 26705854
Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5(4):e185896. https://doi.org/10.1001/jamaoncol.2018.5896 .
doi: 10.1001/jamaoncol.2018.5896
pubmed: 30629084
pmcid: 6459120
Habr-Gama A, Sao Juliao GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269(1):102–7. https://doi.org/10.1097/SLA.0000000000002447 .
doi: 10.1097/SLA.0000000000002447
pubmed: 28742703
Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99(9):1211–8. https://doi.org/10.1002/bjs.8821 .
doi: 10.1002/bjs.8821
pubmed: 22864880
Elmessiry MM, Van Koughnett JA, Maya A, DaSilva G, Wexner SD, Bejarano P et al. Local excision of T1 and T2 rectal cancer: proceed with caution. Colorectal Dis. 2014;16(9):703–9. https://doi.org/10.1111/codi.12657 .
doi: 10.1111/codi.12657
pubmed: 24787457
Swedish Rectal Cancer T, Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist LE et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7. https://doi.org/10.1056/NEJM199704033361402 .
doi: 10.1056/NEJM199704033361402
Fiorica F, Trovo M, Anania G, Marcello D, Di Benedetto F, Marzola M et al. Is it possible a conservative approach after radiochemotherapy in locally advanced rectal cancer (LARC)? A systematic review of the literature and meta-analysis. J Gastrointest Cancer. 2019;50(1):98–108. https://doi.org/10.1007/s12029-017-0041-8 .
doi: 10.1007/s12029-017-0041-8
pubmed: 29273921
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23. https://doi.org/10.1002/bjs.5506 .
doi: 10.1002/bjs.5506
pubmed: 16983741
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33. https://doi.org/10.1200/JCO.2012.42.9597 .
doi: 10.1200/JCO.2012.42.9597
pubmed: 23008301
Bujko K, Pietrzak L, Partycki M, Szczepkowski M, Wyrwicz L, Rupinski M et al. The feasibility of short-course radiotherapy in a watch-and-wait policy for rectal cancer. Acta Oncol. 2017;56(9):1152–4. https://doi.org/10.1080/0284186X.2017.1327721 .
doi: 10.1080/0284186X.2017.1327721
pubmed: 28537787
Cummings MA, Usuki KY, Fleming FJ, Tejani MA, Katz AW. Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided? J Gastrointest Oncol. 2019;10(2):357–61. https://doi.org/10.21037/jgo.2018.09.05 .
doi: 10.21037/jgo.2018.09.05
pubmed: 31032106
pmcid: 6465496
Jia AY, Narang A, Safar B, Zaheer A, Murphy A, Azad NS et al. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. Radiat Oncol. 2019;14(1):147. https://doi.org/10.1186/s13014-019-1358-1 .
doi: 10.1186/s13014-019-1358-1
pubmed: 31426827
pmcid: 6700789
Nilsson PJ, van Etten B, Hospers GA, Pahlman L, van de Velde CJ, Beets-Tan RG et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer. 2013;13:279. https://doi.org/10.1186/1471-2407-13-279 .
doi: 10.1186/1471-2407-13-279
pubmed: 23742033
pmcid: 3680047
Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80. https://doi.org/10.1016/j.ijrobp.2012.05.017 .
doi: 10.1016/j.ijrobp.2012.05.017
pubmed: 22763027
Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071. https://doi.org/10.1001/jamaoncol.2018.0071 .
doi: 10.1001/jamaoncol.2018.0071
pubmed: 29566109
pmcid: 5885165
Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–22. https://doi.org/10.1200/JCO.19.00308 .
doi: 10.1200/JCO.19.00308
pubmed: 31150315
Probst CP, Becerra AZ, Aquina CT, Tejani MA, Wexner SD, Garcia-Aguilar J et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–40. https://doi.org/10.1016/j.jamcollsurg.2015.04.010 .
doi: 10.1016/j.jamcollsurg.2015.04.010
pubmed: 26206642
pmcid: 5014360
Du D, Su Z, Wang D, Liu W, Wei Z. Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2018;17(1):13–24. https://doi.org/10.1016/j.clcc.2017.10.012 .
doi: 10.1016/j.clcc.2017.10.012
pubmed: 29153429
Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46. https://doi.org/10.1016/S1470-2045(17)30086-4 .
doi: 10.1016/S1470-2045(17)30086-4
pubmed: 28190762
Pettersson D, Lorinc E, Holm T, Iversen H, Cedermark B, Glimelius B et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102(8):972–8; discussion 8. https://doi.org/10.1002/bjs.9811 .
doi: 10.1002/bjs.9811
pubmed: 26095256
pmcid: 4744683
Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Sezak M, Ozkok S et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2018;105(11):1417–25. https://doi.org/10.1002/bjs.10984 .
doi: 10.1002/bjs.10984
pubmed: 30155949
Huang Y, Lee D, Young C. Predictors for complete pathological response for stage II and III rectal cancer following neoadjuvant therapy - a systematic review and meta-analysis. Am J Surg. 2020. https://doi.org/10.1016/j.amjsurg.2020.01.001 .
Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9):1750–5. https://doi.org/10.1002/cncr.22625 .
doi: 10.1002/cncr.22625
pubmed: 17387743
Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254(3):486–92; discussion 92-3. https://doi.org/10.1097/SLA.0b013e31822b8cfa .
doi: 10.1097/SLA.0b013e31822b8cfa
pubmed: 21865946
pmcid: 3202983
Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann Surg Oncol. 2016;23(8):2548–55. https://doi.org/10.1245/s10434-016-5205-4 .
doi: 10.1245/s10434-016-5205-4
pubmed: 27020587
pmcid: 5047012
Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One. 2012;7(9):e45388. https://doi.org/10.1371/journal.pone.0045388 .
doi: 10.1371/journal.pone.0045388
pubmed: 23049793
pmcid: 3458025
de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S et al. DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J Clin Oncol. 2016;34(25):3039–46. https://doi.org/10.1200/JCO.2016.66.6826 .
doi: 10.1200/JCO.2016.66.6826
pubmed: 27432916
pmcid: 5012714
McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N et al. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer. 2015;113(12):1677–86. https://doi.org/10.1038/bjc.2015.427 .
doi: 10.1038/bjc.2015.427
pubmed: 26645238
pmcid: 4702002
Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106(10):1381–92. https://doi.org/10.1002/bjs.11179 .
doi: 10.1002/bjs.11179
pubmed: 31197828
Matsutani S, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S et al. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 2018;109(4):966–79. https://doi.org/10.1111/cas.13542 .
doi: 10.1111/cas.13542
pubmed: 29464828
pmcid: 5891199
Maas M, Lambregts DM, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JW et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015;22(12):3873–80. https://doi.org/10.1245/s10434-015-4687-9 .
doi: 10.1245/s10434-015-4687-9
pubmed: 26198074
pmcid: 4595525
van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–45. https://doi.org/10.1016/S0140-6736(18)31078-X .
doi: 10.1016/S0140-6736(18)31078-X
pubmed: 29976470
Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13. https://doi.org/10.1016/S2468-1253(17)30074-2 .
doi: 10.1016/S2468-1253(17)30074-2
pubmed: 28479372
Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol. 2005;23(15):3475–9. https://doi.org/10.1200/JCO.2005.06.114 .
doi: 10.1200/JCO.2005.06.114
pubmed: 15908656
Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57(3):311–5. https://doi.org/10.1097/DCR.0b013e3182a84eba .
doi: 10.1097/DCR.0b013e3182a84eba
pubmed: 24509452
Lambregts DMJ, Delli Pizzi A, Lahaye MJ, van Griethuysen JJM, Maas M, Beets GL et al. A pattern-based approach combining tumor morphology on MRI with distinct signal patterns on diffusion-weighted imaging to assess response of rectal tumors after chemoradiotherapy. Dis Colon Rectum. 2018;61(3):328–37. https://doi.org/10.1097/DCR.0000000000000915 .
doi: 10.1097/DCR.0000000000000915
pubmed: 29369900
Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following "Watch and Wait" for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum. 2017;60(3):335–45. https://doi.org/10.1097/DCR.0000000000000754 .
doi: 10.1097/DCR.0000000000000754
pubmed: 28177997
Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T et al. Organ preservation in rectal cancer: the patients' perspective. Front Oncol. 2019;9:318. https://doi.org/10.3389/fonc.2019.00318 .
doi: 10.3389/fonc.2019.00318
pubmed: 31134146
pmcid: 6524150
Schwartzberg DM, Grieco MJ, Timen M, Grucela AL, Bernstein MA, Wexner SD. Is the whole world watching and waiting? An International Questionnaire on the current practices of 'Watch & Wait' rectal cancer treatment. Colorectal Dis. 2018;20(12):1069. https://doi.org/10.1111/codi.14397 .
doi: 10.1111/codi.14397
pubmed: 30506653